Compare Stocks → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APTXNASDAQ:BPTHNASDAQ:CMRANASDAQ:PXMD Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTXAptinyx$0.10+3.1%$0.08$0.01▼$0.72N/A1.271.32 million shs231,100 shsBPTHBio-Path$2.68+1.9%$4.77$2.35▼$44.80$1.82M0.351.11 million shs117,120 shsCMRAComera Life Sciences$0.04$0.04$0.02▼$0.83$1.11M0.3721,568 shs267 shsPXMDPaxMedica$0.74+5.7%$0.62$0.37▼$29.75$5.53M0.611.91 million shs494,835 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTXAptinyx0.00%0.00%0.00%0.00%-22.33%BPTHBio-Path+5.82%-37.26%-34.45%-71.96%-89.20%CMRAComera Life Sciences-11.95%-11.95%+3.14%-46.12%-95.37%PXMDPaxMedica+1.76%-7.72%+37.86%+42.98%-97.43%Move Your Money Before May 22 (Ad)The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTXAptinyxN/AN/AN/AN/AN/AN/AN/AN/ABPTHBio-Path2.5016 of 5 stars3.55.00.00.02.40.00.6CMRAComera Life SciencesN/AN/AN/AN/AN/AN/AN/AN/APXMDPaxMedica1.5976 of 5 stars3.52.00.00.01.62.50.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTXAptinyxN/AN/AN/AN/ABPTHBio-Path3.00Buy$40.001,392.54% UpsideCMRAComera Life SciencesN/AN/AN/AN/APXMDPaxMedica3.00Buy$3.00305.52% UpsideCurrent Analyst RatingsLatest APTX, CMRA, BPTH, and PXMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.003/27/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $40.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTXAptinyx$1MN/AN/AN/A$0.57 per shareN/ABPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/ACMRAComera Life Sciences$630K1.76N/AN/A($0.37) per share-0.10PXMDPaxMedicaN/AN/AN/AN/A$0.46 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTXAptinyx-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/ABPTHBio-Path-$16.08M-$40.80N/AN/AN/AN/A-375.74%-248.63%5/10/2024 (Estimated)CMRAComera Life Sciences-$18M-$0.49N/A∞N/A-904.00%N/A-297.91%N/APXMDPaxMedica-$18.29M-$24.42N/AN/AN/AN/A-956.84%-388.94%5/20/2024 (Estimated)Latest APTX, CMRA, BPTH, and PXMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/8/202412/31/2023BPTHBio-Path-$5.40-$5.40N/AN/AN/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTXAptinyxN/AN/AN/AN/AN/ABPTHBio-PathN/AN/AN/AN/AN/ACMRAComera Life SciencesN/AN/AN/AN/AN/APXMDPaxMedicaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTXAptinyxN/AN/AN/ABPTHBio-PathN/A1.601.60CMRAComera Life SciencesN/A0.900.90PXMDPaxMedicaN/A3.163.16OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTXAptinyxN/ABPTHBio-Path5.74%CMRAComera Life SciencesN/APXMDPaxMedica4.90%Insider OwnershipCompanyInsider OwnershipAPTXAptinyx10.97%BPTHBio-Path3.05%CMRAComera Life Sciences8.90%PXMDPaxMedica57.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPTXAptinyx12N/AN/ANot OptionableBPTHBio-Path10680,000658,000OptionableCMRAComera Life Sciences1230.74 million28.00 millionNot OptionablePXMDPaxMedica67.47 million3.14 millionNot OptionableAPTX, CMRA, BPTH, and PXMD HeadlinesSourceHeadlinePaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcastfinance.yahoo.com - April 26 at 9:43 AMUrgent Action: PaxMedica (NASDAQ: PXMD) Addresses Medical Crisis in Malawitheglobeandmail.com - April 25 at 1:41 PMPaxMedica (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDAtheglobeandmail.com - April 25 at 2:09 AMPaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101globenewswire.com - April 23 at 8:30 AMPaxMedica, Inc.: PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sicknessfinanznachrichten.de - April 18 at 10:59 PMChoosing Unknown Penny Stocks, 3 Top Tipspennystocks.com - April 15 at 6:39 AMPaxMedica, Inc.: PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submissionfinanznachrichten.de - April 12 at 11:57 PMNasdaq Down 300 Points; BlackRock Posts Upbeat Earningsmarkets.businessinsider.com - April 12 at 6:52 PMBiopharma Stocks in Play - PaxMedica, Inc. (NASDAQ: PXMD) Soars on milestone enabling New Drug Application (NDA) to FDAinvestorideas.com - April 12 at 6:52 PMPenny Stock PaxMedica's African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock Ralliesmsn.com - April 12 at 1:50 PMWhy is PaxMedica (PXMD) stock surging today?invezz.com - April 12 at 11:18 AMWhy Is PaxMedica (PXMD) Stock Up 93% Today?investorplace.com - April 12 at 8:06 AMWhy Is PaxMedica (PXMD) Stock Up 93% Today?investorplace.com - April 12 at 7:51 AMPaxMedica shares soar 125% post-market on drug updatemsn.com - April 11 at 5:55 PMPaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submissionfinance.yahoo.com - April 11 at 5:55 PMPaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submissionglobenewswire.com - April 11 at 4:30 PMPaxMedica (NASDAQ: PXMD) Developing Robust Product Lineup to Address ASD, Associated Conditionstheglobeandmail.com - April 9 at 12:48 PMPaxMedica (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patientstheglobeandmail.com - March 23 at 6:45 PMPaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatmentsglobenewswire.com - March 13 at 8:20 AMPaxMedica Inc Ordinary Shares PXMDmorningstar.com - March 6 at 4:40 PMPaxMedica Stock (NASDAQ:PXMD), Short Interest Reportbenzinga.com - February 23 at 1:33 AMPaxMedica (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals with ASDtheglobeandmail.com - January 29 at 12:42 PMIBN Highlights PaxMedica's Video Release on Transformative ASD Studyfinance.yahoo.com - January 18 at 10:07 AMIBN Highlights PaxMedica’s (NASDAQ: PXMD) Video Release on Transformative ASD Studytheglobeandmail.com - January 17 at 1:35 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAptinyxNASDAQ:APTXAptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.Bio-PathNASDAQ:BPTHBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Comera Life SciencesNASDAQ:CMRAComera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.PaxMedicaNASDAQ:PXMDPaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human African trypanosomiasis (HAT). It also develops PAX-102, an intranasal formulation of suramin, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.